Fig. 6.
Results of treatment with rituximab followed by endostatin.
NOD/SCID mice that received transplants of 10 × 106Namalwa cells intraperitoneally were given 3 courses of rituximab (25 mg/kg) on days 3, 5, and 7 after transplantation and randomly assigned to receive 50 μg of endostatin (⧫) or phosphate-buffered saline (PBS) (▪) on days 15 to 19. In endostatin-treated mice, but not in PBS-treated mice, tumor growth was prevented as long as endostatin was administered. The dotted line indicates tumor growth in untreated controls (▴). Results are mean ± SD values for tumor volume (n = 4 per group).
